Drugs / GSK1614235
GSK1614235
also known as
DSP-3235 · DSP-3235 SEBACATE · GSK-16142353 SEBACATE · GSK-1614235B · KGA-3235 · KGA-3235 SEBACATE · KWA-0711 SEBACATE · Mizagliflozin sebacate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00976261 | Oct 2009 → Sep 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01607385 Comparator | May → Dec 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK-1614235 | “GSK-1614235 and KGA-2727 are potent, selective inhibitors of the SGLT1 sodium-dependent glucose transporter.” PMID 25767259 ↗ Mar 2015 |
| Known as | DSP-3235 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Known as | DSP-3235 SEBACATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Known as | GSK-16142353 SEBACATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Known as | GSK-1614235B | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Known as | KGA-3235 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Known as | KGA-3235 SEBACATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Known as | KWA-0711 SEBACATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Known as | Mizagliflozin sebacate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965 ↗ |
| Action | Inhibit | “GSK-1614235 and KGA-2727 are potent, selective inhibitors of the SGLT1 sodium-dependent glucose transporter.” PMID 25767259 ↗ Mar 2015 |